KRAS and adenocarcinoma: HER2 mutations were detected in 7 of 104 driver mutation-negative (i.e., EGFR/KRAS/ALK/ROS1 negative) adenocarcinomas examined (6.7%), and included mostly insertion mutations in exon 20.